{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:13:25Z","timestamp":1782746005130,"version":"3.54.5"},"reference-count":51,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2024.0003","type":"journal-article","created":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T12:31:03Z","timestamp":1711369863000},"source":"Crossref","is-referenced-by-count":4,"title":["Phenibut\u2014an illegal food supplement with psychotropic effects and health risks"],"prefix":"10.3238","author":[{"given":"Udo","family":"Bonnet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Scherbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schaper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Soyka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"10.3238\/arztebl.m2024.0003_ref1","doi-asserted-by":"crossref","unstructured":"Lapin I: Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev 2001; 7: 471–81.","DOI":"10.1111\/j.1527-3458.2001.tb00211.x"},{"key":"10.3238\/arztebl.m2024.0003_ref2","doi-asserted-by":"crossref","unstructured":"Kupats E, Vrublevska J, Zvejniece B, et al.: Safety and tolerability of the anxiolytic and nootropic drug phenibut: a systematic review of clinical trials and case reports. Pharmacopsychiatry 2020; 53: 201–8.","DOI":"10.1055\/a-1151-5017"},{"key":"10.3238\/arztebl.m2024.0003_ref3","doi-asserted-by":"crossref","unstructured":"Bonnet U, Scherbaum N: [On the risk of dependence on gabapentinoids]. Fortschr Neurol Psychiatr 2018; 86: 82–105.","DOI":"10.1055\/s-0043-122392"},{"key":"10.3238\/arztebl.m2024.0003_ref4","doi-asserted-by":"crossref","unstructured":"Calandre EP, Rico-Villademoros F, Slim M: Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use. Expert Rev Neurother 2016; 16: 1263–77.","DOI":"10.1080\/14737175.2016.1202764"},{"key":"10.3238\/arztebl.m2024.0003_ref5","doi-asserted-by":"crossref","unstructured":"McCabe DJ, Bangh SA, Arens AM, Cole JB: Phenibut exposures and clinical effects reported to a regional poison center. Am J Emerg Med 2019; 37: 2066–71.","DOI":"10.1016\/j.ajem.2019.02.044"},{"key":"10.3238\/arztebl.m2024.0003_ref6","doi-asserted-by":"crossref","unstructured":"Evoy KE, Peckham AM, Covvey JR, Tidgewell KJ: Gabapentinoid pharmacology in the context of emerging misuse liability. J Clin Pharmacol 2021; 61 (Suppl 2): S89–S99.","DOI":"10.1002\/jcph.1833"},{"key":"10.3238\/arztebl.m2024.0003_ref7","doi-asserted-by":"crossref","unstructured":"Graves JM, Dilley J, Kubsad S, Liebelt E: Notes from the field: phenibut exposures reported to poison centers—United States, 2009–2019. MMWR Morb Mortal Wkly Rep 2020; 69: 1227–8.","DOI":"10.15585\/mmwr.mm6935a5"},{"key":"10.3238\/arztebl.m2024.0003_ref8","doi-asserted-by":"crossref","unstructured":"Behmer Hansen RA, Behmer Hansen RT, Noureddine C, Behmer VA, Opler D: Reasons for use and experiences of using phenibut, a mixed methods analysis of online reports. Am J Drug Alcohol Abuse 2023; 49: 458–69.","DOI":"10.1080\/00952990.2023.2204510"},{"key":"10.3238\/arztebl.m2024.0003_ref9","doi-asserted-by":"crossref","unstructured":"Arndt C, Gray TR: Phenibut, a GABA-B agonist, detected in a fatality. J Anal Toxicol 2021 [Epub ahead of print].","DOI":"10.1093\/jat\/bkab099"},{"key":"10.3238\/arztebl.m2024.0003_ref10","doi-asserted-by":"crossref","unstructured":"Papsun DM, Chan-Hosokawa A, Friederich L, Brower J, Graf K, Logan B: The trouble with kratom: analytical and interpretative issues involving mitragynine. J Anal Toxicol 2019; 43: 615–29.","DOI":"10.1093\/jat\/bkz064"},{"key":"10.3238\/arztebl.m2024.0003_ref11","doi-asserted-by":"crossref","unstructured":"Jouney EA: Phenibut (β-phenyl-γ-aminobutyric acid): an easily obtainable “dietary supplement” with propensities for physical dependence and addiction. Curr Psychiatry Rep 2019; 21: 23.","DOI":"10.1007\/s11920-019-1009-0"},{"key":"10.3238\/arztebl.m2024.0003_ref12","doi-asserted-by":"crossref","unstructured":"Hardman MI, Sprung J, Weingarten TN: Acute phenibut withdrawal: a comprehensive literature review and illustrative case report. Bosn J Basic Med Sci 2019; 19: 125–9.","DOI":"10.17305\/bjbms.2018.4008"},{"key":"10.3238\/arztebl.m2024.0003_ref13","doi-asserted-by":"crossref","unstructured":"Jędrejko K, Catlin O, Stewart T, Anderson A, Muszyńska B, Catlin DH: Unauthorized ingredients in “nootropic“ dietary supplements: a review of the history, pharmacology, prevalence, international regulations, and potential as doping agents. Drug Test Anal 2023; 15: 803–39.","DOI":"10.1002\/dta.3529"},{"key":"10.3238\/arztebl.m2024.0003_ref14","doi-asserted-by":"crossref","unstructured":"Weleff J, Kovacevich A, Burson J, Nero N, Anand A: Clinical presentations and treatment of phenibut toxicity and withdrawal: a systematic literature review. J Addict Med 2023; 17: 407–17.","DOI":"10.1097\/ADM.0000000000001141"},{"key":"10.3238\/arztebl.m2024.0003_ref15","unstructured":"Bundesministerium f\u00fcr Gesundheit: Das Neue-psychoaktive-Stoffe-Gesetz (NpSG). www.bundesgesundheitsministerium.de\/service\/begriffe-von-a-z\/n\/npsg.html (last accessed on 11 November 2023)."},{"key":"10.3238\/arztebl.m2024.0003_ref16","doi-asserted-by":"crossref","unstructured":"Morris M, Espinosa J, Lucerna A, Lahr R: A case of phenibut withdrawal and treatment with baclofen. World J Emerg Med 2023; 14: 338–40.","DOI":"10.5847\/wjem.j.1920-8642.2023.059"},{"key":"10.3238\/arztebl.m2024.0003_ref17","doi-asserted-by":"crossref","unstructured":"Scherbaum N, Bonnet U: [Neurobiology of Opiat dependence]. Anaesthesist 2019; 68: 179–90.","DOI":"10.1007\/s00101-019-0557-3"},{"key":"10.3238\/arztebl.m2024.0003_ref18","unstructured":"aerzteblatt.de: US-Beh\u00f6rden wollen versch\u00e4rft gegen illegalen Import von Xylazin vorgehen. Tagesaktuelle Nachrichten vom 10.03.2023. www.aerzteblatt.de\/nachrichten\/141384\/US-Behoerden-wollen-verschaerft-gegen-illegalen-Import-von-Xylazin-vorgehen (last accessed on 3 December 2023)."},{"key":"10.3238\/arztebl.m2024.0003_ref19","unstructured":"FDA-Warning: FDA alerts health care professionals of risks to patients exposed to xylazine in illicit drugs. 1\/08\/2022. www.fda.gov\/drugs\/drug-safety-and-availability\/fda-alerts-health-care-professionals-risks-patients-exposed-xylazine-illicit-drugs (last accessed on 5 January 2024)."},{"key":"10.3238\/arztebl.m2024.0003_ref20","doi-asserted-by":"crossref","unstructured":"Komisarek D, Taskiran E, Vasylyeva V: Maleic acid as a co-former for pharmaceutically active GABA derivatives: mechanochemistry or solvent crystallization? Materials (Basel) 2023; 16: 2242.","DOI":"10.3390\/ma16062242"},{"key":"10.3238\/arztebl.m2024.0003_ref21","doi-asserted-by":"crossref","unstructured":"Dambrova M, Zvejniece L, Liepinsh E, et al.: Comparative pharmacological activity of optical isomers of phenibut. Eur J Pharmacol 2008; 583: 128–34.","DOI":"10.1016\/j.ejphar.2008.01.015"},{"key":"10.3238\/arztebl.m2024.0003_ref22","doi-asserted-by":"crossref","unstructured":"Zvejniece L, Vavers E, Svalbe B, et al.: R-phenibut binds to the α2-δ subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects. Pharmacol Biochem Behav 2015; 137: 23–9.","DOI":"10.1016\/j.pbb.2015.07.014"},{"key":"10.3238\/arztebl.m2024.0003_ref23","doi-asserted-by":"crossref","unstructured":"Belozertseva I, Nagel J, Valastro B, Franke L, Danysz W: Optical isomers of phenibut inhibit [H(3)]-gabapentin binding in vitro and show activity in animal models of chronic pain. Pharmacol Rep 2016; 68: 550–4.","DOI":"10.1016\/j.pharep.2015.12.004"},{"key":"10.3238\/arztebl.m2024.0003_ref24","doi-asserted-by":"crossref","unstructured":"Bonnet U: Gabapentinoide: entwichen aus der B\u00fcchse der Pandora? DNP 2022; 23: 32–8.","DOI":"10.1007\/s15202-022-4834-7"},{"key":"10.3238\/arztebl.m2024.0003_ref25","unstructured":"Irsfeld M, Spadafore M, Pr\u00fc\u00df BM: β-phenylethylamine, a small molecule with a large impact. Webmedcentral 2013; 4: 4409."},{"key":"10.3238\/arztebl.m2024.0003_ref26","doi-asserted-by":"crossref","unstructured":"Martin R, Buffenstein I, Cho D, Kiyokawa M: Toxidrome of an easily obtainable nootropic: a case report of phenibut intoxication and withdrawal delirium. J Clin Psychopharmacol 2023; 43: 507–10.","DOI":"10.1097\/JCP.0000000000001759"},{"key":"10.3238\/arztebl.m2024.0003_ref27","doi-asserted-by":"crossref","unstructured":"Nedzlek CD, Michaelis A: An unusual presentation of an uncommon drug: a case report on phenibut overdose. Cureus 2022; 14: e23913.","DOI":"10.7759\/cureus.23913"},{"key":"10.3238\/arztebl.m2024.0003_ref28","doi-asserted-by":"crossref","unstructured":"Doyno CR, White CM: Sedative-hypnotic agents that impact gamma-aminobutyric acid receptors: focus on flunitrazepam, gamma-hydroxybutyric acid, phenibut, and selank. J Clin Pharmacol 2021; 61 (Suppl 2): S114–28.","DOI":"10.1002\/jcph.1922"},{"key":"10.3238\/arztebl.m2024.0003_ref29","doi-asserted-by":"crossref","unstructured":"Dolphin AC: Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. J Physiol 2016; 594: 5369–90.","DOI":"10.1113\/JP272262"},{"key":"10.3238\/arztebl.m2024.0003_ref30","doi-asserted-by":"crossref","unstructured":"Reddy DS: An enigmatic role of tonic inhibition in gabapentin therapy. EBioMedicine. 2019; 42: 14–15.","DOI":"10.1016\/j.ebiom.2019.03.047"},{"key":"10.3238\/arztebl.m2024.0003_ref31","doi-asserted-by":"crossref","unstructured":"Brunner E, Levy R: Case report of physiologic phenibut dependence treated with a phenobarbital taper in a patient being treated with buprenorphine. J Addict Med 2017; 11: 239–40.","DOI":"10.1097\/ADM.0000000000000303"},{"key":"10.3238\/arztebl.m2024.0003_ref32","unstructured":"Kraus L, Schiemann A, Verthein U: Evaluation der Auswirkungen des Neue-psychoaktive-Stoffe-Gesetzes (NpSG): Abschlussbericht. Institut f\u00fcr Therapieforschung. 2019. www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwimtO_3loKAAxWsRPEDHZQFDE4QFnoECBAQAQ&url=https%3A%2F%2Fift.de%2Fwp-content%2Fuploads%2F2022%2F08%2FKraus_et_al_2020_NpSG-Abschlussbericht.pdf&usg=AOvVaw3pcpnLE2W0X3B2Da_K2oAb&opi=89978449 (last accessed on 11 November 2023)."},{"key":"10.3238\/arztebl.m2024.0003_ref33","doi-asserted-by":"crossref","unstructured":"Penninga EI, Graudal N, Ladekarl MB, J\u00fcrgens G: Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication—a systematic review with meta-analyses of randomised trials. Basic Clin Pharmacol Toxicol 2016; 118: 37–44.","DOI":"10.1111\/bcpt.12434"},{"key":"10.3238\/arztebl.m2024.0003_ref34","doi-asserted-by":"crossref","unstructured":"Bonnet U, McAnally HB: How prevalent and severe is addiction on GABAmimetic drugs in an elderly German general hospital population? Focus on gabapentinoids, benzodiazepines, and z-hypnotic drugs. Hum Psychopharmacol 2022; 37: e2822.","DOI":"10.1002\/hup.2822"},{"key":"10.3238\/arztebl.m2024.0003_ref35","doi-asserted-by":"crossref","unstructured":"Bonnet U, Specka M, Soyka M, et al.: Ranking the harm of psychoactive drugs including prescription analgesics to users and others—a perspective of German addiction medicine experts. Front Psychiatry 2020; 11: 592199.","DOI":"10.3389\/fpsyt.2020.592199"},{"key":"10.3238\/arztebl.m2024.0003_ref36","doi-asserted-by":"crossref","unstructured":"Soyka M: Treatment of benzodiazepine dependence. N Engl J Med 2017; 376: 1147–57.","DOI":"10.1056\/NEJMra1611832"},{"key":"10.3238\/arztebl.m2024.0003_ref37","doi-asserted-by":"crossref","unstructured":"Mokrousov IS, Perfilova VN, Prokofiev II, et al.: Effect of a new cyclic derivative of GABA, RGPU-207, on the functions of cardiac and cerebral mitochondria of stressed animals. J Pharm Pharmacol 2019; 71: 1055–64.","DOI":"10.1111\/jphp.13086"},{"key":"10.3238\/arztebl.m2024.0003_ref38","doi-asserted-by":"crossref","unstructured":"Vavers E, Zvejniece L, Svalbe B, et al.: The neuroprotective effects of R-phenibut after focal cerebral ischemia. Pharmacol Res 2016; 113 (Pt B): 796–801.","DOI":"10.1016\/j.phrs.2015.11.013"},{"key":"10.3238\/arztebl.m2024.0003_ref39","unstructured":"Volotova EV, Filina IS, Bakulin DA, Kurkin DV, Tyurenkov IN: Neuroprotective action of phenibut and neuroglutam in experimental cerebral ischemia on the background of altered immunoreactivity. Eksp Klin Farmakol 2016; 79: 18–25."},{"key":"10.3238\/arztebl.m2024.0003_ref40","doi-asserted-by":"crossref","unstructured":"Persson HE, Sj\u00f6berg GK, Haines JA, Pronczuk de Garbino J: Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol 1998; 36: 205–13.","DOI":"10.3109\/15563659809028940"},{"key":"10.3238\/arztebl.m2024.0003_ref41","doi-asserted-by":"crossref","unstructured":"Bonnet U, Kanti AK, Scherbaum N, Specka M: The role of gabapentinoids in the substance use pattern of adult Germans seeking inpatient detoxification treatment—a pilot study. J Psychoactive Drugs 2023; 55: 102–111.","DOI":"10.1080\/02791072.2022.2050858"},{"key":"10.3238\/arztebl.m2024.0003_ref42","doi-asserted-by":"crossref","unstructured":"Liu JY, Guo F, Wu HL, Wang Y, Liu JS: Midazolam anesthesia protects neuronal cells from oxidative stress-induced death via activation of the JNK-ERK pathway. Mol Med Rep 2017; 15: 169–79.","DOI":"10.3892\/mmr.2016.6031"},{"key":"10.3238\/arztebl.m2024.0003_ref43","unstructured":"Kumar A, Goyal R: Gabapentin attenuates acute hypoxic stress-induced behavioral alterations and oxidative damage in mice: possible involvement of GABAergic mechanism. Indian J Exp Biol 2008; 46: 159–63."},{"key":"10.3238\/arztebl.m2024.0003_ref44","doi-asserted-by":"crossref","unstructured":"Yan BC, Wang J, Rui Y, et al.: Neuroprotective effects of gabapentin against cerebral ischemia reperfusion-induced neuronal autophagic injury via regulation of the PI3K\/Akt\/mTOR signaling pathways. J Neuropathol Exp Neurol 2019; 78: 157–71.","DOI":"10.1093\/jnen\/nly119"},{"key":"10.3238\/arztebl.m2024.0003_ref45","doi-asserted-by":"crossref","unstructured":"Taha SHN, Zaghloul HS, Ali AAER, Gaballah IF, Rashed LA, Aboulhoda BE: The neurotoxic effect of long-term use of high-dose pregabalin and the role of alpha tocopherol in amelioration: implication of MAPK signaling with oxidative stress and apoptosis. Naunyn Schmiedebergs Arch Pharmacol 2020; 393: 1635–48.","DOI":"10.1007\/s00210-020-01875-5"},{"key":"10.3238\/arztebl.m2024.0003_ref46","doi-asserted-by":"crossref","unstructured":"Soyalp C, Oksuz E, Gorgisen G, et al.: Role of sedative-hypnotic agents in neurodegeneration: effects of midazolam and thiopental on apoptosis and oxidative stress expression in neonatal and adult rat brains. Turk Neurosurg 2022; 32: 378–85.","DOI":"10.5137\/1019-5149.JTN.32324-20.2"},{"key":"10.3238\/arztebl.m2024.0003_ref47","doi-asserted-by":"crossref","unstructured":"Andrews PW, Kornstein SG, Halberstadt LJ, Gardner CO, Neale MC: Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol 2011; 2: 159.","DOI":"10.3389\/fpsyg.2011.00159"},{"key":"10.3238\/arztebl.m2024.0003_ref48","doi-asserted-by":"crossref","unstructured":"Cahill CM, Walwyn W, Taylor AMW, Pradhan AAA, Evans CJ: Allostatic mechanisms of opioid tolerance beyond desensitization and downregulation. Trends Pharmacol Sci 2016; 37: 963–76.","DOI":"10.1016\/j.tips.2016.08.002"},{"key":"10.3238\/arztebl.m2024.0003_ref49","doi-asserted-by":"crossref","unstructured":"Koob GF: Drug addiction: hyperkatifeia\/negative reinforcement as a framework for medications development. Pharmacol Rev 2021; 73: 163–201.","DOI":"10.1124\/pharmrev.120.000083"},{"key":"10.3238\/arztebl.m2024.0003_ref50","doi-asserted-by":"crossref","unstructured":"Konstantinopolsky MA, Chernyakova IV, Kolik LG: Selank, a peptide analog of tuftsin, attenuates aversive signs of morphine withdrawal in rats. Bull Exp Biol Med 2022; 173: 730–3.","DOI":"10.1007\/s10517-022-05624-x"},{"key":"10.3238\/arztebl.m2024.0003_ref51","doi-asserted-by":"crossref","unstructured":"Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N: Peptide-based anxiolytics: the molecular aspects of heptapeptide selank biological activity. Protein Pept Lett 2018; 25: 914–23.","DOI":"10.2174\/0929866525666180925144642"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T12:31:38Z","timestamp":1711369898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":51,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2024.0003","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]}}}